Abstract:Boron neutron capture therapy (BNCT) is a highly targeted, selective and effective technique to cure various types of cancers, with less harm to the healthy cells. In principle, BNCT treatment needs to distribute the 10boron (10B) atoms inside the tumor tissues, selectively and homogeneously, as well as to initiate a nuclear fission reaction by capturing sufficient neutrons which releases high linear energy particles to kill the tumor cells. In BNCT, it is crucial to have high quality boron agents with acceptable bio-selectivity, homogeneous distribution and deliver in required quantity, similar to chemotherapy and other radiotherapy for tumor treatment. Nevertheless, boron drugs currently used in clinical trials yet to meet the full requirements. On the other hand, BNCT processing has opened up the era of renaissance due to the advanced development of the high-quality neutron source and the global construction of new BNCT centers. Consequently, there is an urgent need to use boron agents that have increased biocapacity. Artificial intelligence (AI) tools such as molecular docking and molecular dynamic simulation technologies have been utilized to develop new medicines. In this work, the in silico assessments including bioinformatics assessments of BNCT related tumoral receptor proteins, computational assessments of optimized small molecules of boron agents, are employed to speed up the screening process for boron drugs. The outcomes will be applicable to pave the way for future BNCT that utilizes artificial intelligence. The in silico molecular docking and dynamic simulation results of the optimized small boron agents, such as 4-borono-l-phenylalanine (BPA) with optimized proteins like the L-type amino acid transporter 1 (LTA1, also known as SLC7A5) will be examined. The in silico assessments results will certainly be helpful to researchers in optimizing druggable boron agents for the BNCT application. The clinical status of the optimized proteins, which are highly relevant to cancers that may be treated with BNCT, has been assessed using bioinformatics technology and discussed accordingly. Furthermore, the evaluations of cytotoxicity (IC50), boron uptake and tissue distribution of the optimized ligands 1 and 7 have been presented.

Medicinal electronomics bricolage design of hypoxia-targeting antineoplastic drugs and invention of boron tracedrugs as innovative future-architectural drugs

Catalytic Modulation of the Tumor Microenvironment Using Cascade Enzymes for Synergistic Boron Neutron Capture Therapy in the Treatment of Gliomas

Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals

Multi-Functional Boron-Delivery Agents for Boron Neutron Capture Therapy of Cancers

Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT

In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy

Recent developments in the medicinal chemistry of single boron atom-containing compounds

New Boron Delivery Agents

The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry

The Dawn of a New Era: Tumor-Targeting Boron Agents for Neutron Capture Therapy

Boronotyrosine, a Borylated Amino Acid Mimetic with Enhanced Solubility, Tumor Boron Delivery, and Retention for the Re-emerging Boron Neutron Capture Therapy Field

Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs

Chemical Design And Synthesis Of Functionalized Probes For Imaging And Treating Tumor Hypoxia

Optimizing Boron Neutron Capture Therapy (BNCT) to Treat Cancer: An Updated Review on the Latest Developments on Boron Compounds and Strategies

Boron Chemistry for Medical Applications

Biomimetic Boron Nitride Nanoparticles for Targeted Drug Delivery and Enhanced Antitumor Activity

Molecular Engineering of AIE-active Boron Clustoluminogens for Enhanced Boron Neutron Capture Therapy.

Construction of targeted 10B delivery agents and their uptake in gastric and pancreatic cancer cells

Rational Design, Multistep Synthesis and in Vitro Evaluation of Poly(glycerol) Functionalized Nanodiamond Conjugated with Boron-10 Cluster and Active Targeting Moiety for Boron Neutron Capture Therapy

Theranostics in Boron Neutron Capture Therapy

Nanostructured boron agents for boron neutron capture therapy: a review of recent patents